Edgewise Therapeutics, Inc. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Edgewise Therapeutics, Inc. (EWTX) had Fair Value, Assets, Level 2 to Level 1 Transfers, Amount of $0 as of 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount · last filed 2022-05-11
- 2022-03-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |